Journal
EUROPEAN UROLOGY FOCUS
Volume 7, Issue 2, Pages 254-257Publisher
ELSEVIER
DOI: 10.1016/j.euf.2021.02.006
Keywords
Prostate-specific membrane antigen; Prostate cancer; Radionuclide; Targeted radionuclide therapy; Bispecific antibodies; Monoclonal antibodies
Categories
Funding
- U.S. Department of Defense [W81XWH-17-PCRP-IA]
- Prostate Cancer Foundation Challenge Award
- ASCO Conquer Cancer Foundation Young Investigator Award
Ask authors/readers for more resources
PSMA is a clinically validated target for prostate cancer, with therapies using radioactive particles, drugs, or immune agents for treatment.
Prostate-specific membrane antigen (PSMA) is a clinically validated target for prostate cancer. A variety of PSMA-based therapies, including radionuclide- and cytotoxic drug-conjugated and cellular immune products, are in development, each with variable advantages and disadvantages. Here we briefly describe the landscape of PSMA-based therapies beyond Lu-177-PSMA-617, which is covered elsewhere. Patient summary: Prostate-specific membrane antigen (PSMA) is a protein expressed on most prostate cancer tumors and on limited other areas in the body. It can be targeted to treat prostate cancer using radioactive particles, drugs, or immune agents. (C) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
